Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

PHASE2RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2029

Conditions
Breast CancerTriple Negative Breast CancerPD-L1 Negative
Interventions
DRUG

Sacituzumab Govitecan

Intravenous Infusion

DRUG

Pembrolizumab

Intravenous Infusion

Trial Locations (12)

19104

RECRUITING

University of Pennsylvania-Abramson Cancer Center, Philadelphia

27599

RECRUITING

The University of North Carolina at Chapel Hill, Chapel Hill

29425

RECRUITING

Medical University of South Carolina, Charleston

37404

RECRUITING

Sarah Cannon Research Institute, Chattanooga

43212

RECRUITING

Ohio State University Medical Center, Columbus

60637

RECRUITING

University of Chicago Medical Center, Chicago

06904

RECRUITING

Stamford Hospital, Stamford

04412

RECRUITING

Eastern Maine Medical Center, Brewer

02215

RECRUITING

Dana Farber Cancer Institute, Boston

02035

RECRUITING

DFCI @ Foxborough, Foxborough

01757

RECRUITING

DFCI @ Milford Regional Hospital, Milford

02190

RECRUITING

DF/BWCC in Clinical Affiliation with South Shore Hospital, South Weymouth

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER